{
  "ticker": "IDYA",
  "company_name": "IDEAYA Biosciences, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07015190",
      "title": "Neoadjuvant Darovasertib in Primary Uveal Melanoma",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "Uveal Melanoma",
      "start_date": "2025-10",
      "completion_date": "2031-03",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    },
    {
      "nct_id": "NCT06710847",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer",
      "start_date": "2024-12-13",
      "completion_date": "2028-06-16",
      "enrollment": 0,
      "sponsor": "GlaxoSmithKline"
    },
    {
      "nct_id": "NCT03947385",
      "title": "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors",
      "start_date": "2019-06-28",
      "completion_date": "2027-06-15",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    },
    {
      "nct_id": "NCT07174583",
      "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3",
      "start_date": "2025-10-14",
      "completion_date": "2029-05",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    },
    {
      "nct_id": "NCT05787587",
      "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC",
      "start_date": "2023-04-05",
      "completion_date": "2027-05",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    },
    {
      "nct_id": "NCT07277413",
      "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC",
      "start_date": "2026-02-28",
      "completion_date": "2028-04-30",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    },
    {
      "nct_id": "NCT05907954",
      "title": "(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Uveal Melanoma",
      "start_date": "2023-07-03",
      "completion_date": "2030-04-30",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    },
    {
      "nct_id": "NCT05987332",
      "title": "IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Metastatic Uveal Melanoma",
      "start_date": "2023-10-31",
      "completion_date": "2028-01-15",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    },
    {
      "nct_id": "NCT04794699",
      "title": "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Solid Tumor",
      "start_date": "2021-04-14",
      "completion_date": "2027-03-30",
      "enrollment": 0,
      "sponsor": "IDEAYA Biosciences"
    }
  ],
  "summary": {
    "total_trials": 9,
    "by_phase": {
      "PHASE3": 1,
      "PHASE1, PHASE2": 3,
      "PHASE1": 3,
      "PHASE2": 1,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "RECRUITING": 9
    },
    "active_trials": 9,
    "completed_trials": 0,
    "conditions": [
      "Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC",
      "Metastatic Uveal Melanoma",
      "Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors",
      "NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC",
      "Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer",
      "Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3",
      "Solid Tumor",
      "Uveal Melanoma"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:18:55.832422",
    "search_query": "IDEAYA Biosciences, Inc.",
    "url": "https://clinicaltrials.gov/search?term=IDEAYA+Biosciences,+Inc."
  }
}